Regulation and consequences of LRRK2 phosphorylation, a path to Parkinson’s disease therapy and diagnostics

Project Information

RECOLOR

Grant agreement ID: 659183

DOI 10.3030/659183

Project closed

EC signature date 21 April 2015

Start date 1 June 2015

End date 31 May 2017

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 185 076,00

EU contribution € 185 076,00

Coordinated by

UNIVERSITE DE LILLE
France

Publications

Peer reviewed articles (3)

LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker?

Author(s): Jean-Marc Taymans, Eugénie Mutez, Matthieu Drouyer, William Sibran, Marie-Christine Chartier-Harlin
Published in: Biochemical Society Transactions, Issue 45/1, 2017, Page(s) 207-212, ISSN 0300-5127
Publisher: Portland Press, Ltd.
DOI: 10.1042/BST20160334

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Author(s): Jean-Marc Taymans, Elisa Greggio
Published in: Current Neuropharmacology, Issue 14/3, 2016, Page(s) 214-225, ISSN 1570-159X
Publisher: Bentham Science Publishers
DOI: 10.2174/1570159X13666151030102847

Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes

Author(s): Kushal Sejwal, Mohamed Chami, Hervé Rémigy, Renée Vancraenenbroeck, William Sibran, Rosmarie Sütterlin, Paul Baumgartner, Robert McLeod, Marie-Christine Chartier-Harlin, Veerle Baekelandt, Henning Stahlberg, Jean-Marc Taymans
Published in: Scientific Reports, Issue 7/1, 2017, Page(s) 8667, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-017-09126-z